Al San­drock prunes his post-Bio­gen voy­age with sim­i­lar fo­cus on ALS

Al San­drock is nar­row­ing the fo­cus of Voy­ager Ther­a­peu­tics, con­cen­trat­ing on CNS dis­eases that were the hall­mark of his time lead­ing R&D at Bio­gen, in­clud­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER